PDS Biotechnology (NASDAQ:PDSB) Announces Earnings Results

PDS Biotechnology (NASDAQ:PDSB) posted its quarterly earnings results on Tuesday. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.08, Yahoo Finance reports. During the same quarter last year, the business earned ($0.37) earnings per share.

PDS Biotechnology Price Performance

Shares of PDS Biotechnology stock traded up $0.31 during midday trading on Thursday, hitting $3.33. 188,754 shares of the company were exchanged, compared to its average volume of 716,079. The firm has a 50 day simple moving average of $3.26 and a 200-day simple moving average of $3.91. The company has a debt-to-equity ratio of 0.45, a current ratio of 4.56 and a quick ratio of 4.56. The firm has a market cap of $122.14 million, a P/E ratio of -2.22 and a beta of 1.91. PDS Biotechnology has a 52 week low of $2.53 and a 52 week high of $6.85.

Wall Street Analyst Weigh In

PDSB has been the topic of several research reports. Cantor Fitzgerald restated an “overweight” rating on shares of PDS Biotechnology in a research note on Thursday, May 9th. B. Riley reduced their target price on PDS Biotechnology from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Wednesday, June 12th. Finally, HC Wainwright reiterated a “buy” rating and set a $21.00 price target on shares of PDS Biotechnology in a research note on Thursday, August 1st. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $16.67.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.